Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Victory Pharma to Pay $11.4 Million in Kickbacks Probe
Bloomberg
Thursday, December 27, 2012 - 10:39pm
tags:
Victory Pharma, kickbacks
Mylan Suit Against FDA Over Generic Heart Drug Dismissed
Bloomberg
Thursday, December 27, 2012 - 10:35pm
tags:
generics, Mylan, FDA, Diovan
Japan gives initial OK to Novo's insulin combo, Ryzodeg
Fierce Pharma
Thursday, December 27, 2012 - 10:32pm
tags:
Japan, Novo Nordisk, Ryzodeg
The Most Important New Drug Of 2012
Forbes
Thursday, December 27, 2012 - 10:26pm
tags:
Kalydeco, cystic fibrosis, Vertex Pharmaceuticals
How Abbott Labs Succeeded in 2012
Motley Fool
Thursday, December 27, 2012 - 10:23pm
tags:
Abbott Laboratories
Patient in trial of Astex drug achieves complete remission, Pediatrics says
Yahoo/Fly on the Wall
Thursday, December 27, 2012 - 10:22pm
tags:
Astex, decitabine
Keep an Eye on These Five New Drugs in the First Quarter of 2013
Minyanville
Thursday, December 27, 2012 - 10:16pm
tags:
Rytary, GSK, Impax Labs, Celgene, pomalidomide, Roche, T-DM1, Immunogen, Eliquis, Pfizer, Bristol-Myers Squibb, Biogen Idec, BG-12
Pfizer’s Backing Spurs Halozyme's Growth
Motley Fool
Thursday, December 27, 2012 - 10:11pm
tags:
Pfizer, Halozyme, Enhanze
Is Amarin Still a Buy?
Motley Fool
Thursday, December 27, 2012 - 10:10pm
tags:
Amarin
J&J Declines to Comment on U.S. Approval of Sanofi Deal
Bloomberg
Thursday, December 27, 2012 - 10:09pm
tags:
JNJ, Sanofi, antitrust
Does Lilly's Lineup Make the Grade?
Motley Fool
Thursday, December 27, 2012 - 10:08pm
tags:
Eli Lilly
Is Celgene in Good Hands?
Motley Fool
Thursday, December 27, 2012 - 7:59am
tags:
Celgene
3 Drug Disappointments From 2012
Motley Fool
Wednesday, December 26, 2012 - 9:33pm
tags:
Zaltrap, Sanofi, Amarin, Vascepa, Qsymia, Arena Pharmaceuticals
A Comprehensive Analysis Of NPS Pharmaceuticals
Seeking Alpha
Wednesday, December 26, 2012 - 9:29pm
tags:
NPS Pharmaceuticals
Key Dates For Arena And Orexigen Investors
Seeking Alpha
Wednesday, December 26, 2012 - 9:25pm
tags:
Orexigen, Contrave, Belviq, Arena Pharmaceuticals, Qsymia, Vivus, obesity
Actelion Drug to Move into Phase III
Yahoo/Zacks
Wednesday, December 26, 2012 - 9:24pm
tags:
Actelion, cadazolid, Clostridium Difficile
Depomed Announces Dismissal Of Suit Against Two Gralise ANDA Filers Following Withdrawal Of ANDA And Patent Challenge
Yahoo
Wednesday, December 26, 2012 - 9:23pm
tags:
Gralise, Depomed
This Beaten Down Drug Company Can Provide Value in 2013
Motley Fool
Wednesday, December 26, 2012 - 9:22pm
tags:
Merck
Several Reasons Why I'm Considering These 2 Biotech Firms Before Year's End
Seeking Alpha
Wednesday, December 26, 2012 - 9:21pm
tags:
Raptor Pharmaceuticals, Aegerion
Ironwood commences first phase of anxiety drug trial in US
Pharmaceutical Business Review
Wednesday, December 26, 2012 - 12:05pm
tags:
Ironwood Pharmaceuticals, anxiety, IW-2143

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.